Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 9.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,605 shares of the company’s stock after selling 1,664 shares during the quarter. Martingale Asset Management L P’s holdings in Vaxcyte were worth $1,783,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter worth about $27,000. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Fifth Third Bancorp acquired a new stake in shares of Vaxcyte during the second quarter valued at about $35,000. J.Safra Asset Management Corp increased its position in shares of Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after acquiring an additional 526 shares during the last quarter. Finally, Meeder Asset Management Inc. increased its position in shares of Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $94.34 on Monday. The stock’s 50-day moving average is $105.60 and its two-hundred day moving average is $90.49. Vaxcyte, Inc. has a 1-year low of $50.04 and a 1-year high of $121.06. The company has a market cap of $11.76 billion, a price-to-earnings ratio of -20.51 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) earnings per share. Equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PCVX shares. Jefferies Financial Group lifted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research note on Wednesday, November 6th. BTIG Research lifted their target price on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Mizuho lifted their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Finally, Leerink Partners lifted their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $147.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total value of $245,803.74. Following the transaction, the chief executive officer now directly owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 1.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares in the company, valued at $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,464 shares of company stock valued at $11,455,576 over the last quarter. 3.10% of the stock is owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.